A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer
This is a proof of concept study (a study to initially assess the benefit a new drug
indication) of the combination of two investigational drugs cediranib and olaparib in
patients with ovarian cancer whose cancer worsened despite previously receiving a poly
(ADP-ribose) polymerase (PARP) inhibitor (such as olaparib).
The purpose of this study is to find out whether taking cediranib and olaparib at the same
time will be able to stop tumours from growing further or shrink it.
Cediranib works by blocking (inhibiting) several specific proteins in cancer cells called
the vascular endothelial growth factor (VEGF) receptors. These proteins are important in the
formation of blood vessels to the tumour. It is believed that many tumours survive because the
blood vessels on the tumours bring oxygen and nutrients to the cancer cells which enable them
to grow. If the formation of the blood vessels is blocked, the tumour cells may die.
Olaparib, works by blocking a protein called poly [adenosine diphosphate-ribose] polymerase
(PARP). PARP is an important protein which tries to fix damaged deoxyribonucleic acid (DNA,
molecules that contain important instructions for the development of cells). Many cancers
are thought to develop from damaged DNA. By blocking PARP from fixing damaged DNA, the tumour
cells may die.
Adding cediranib to olaparib, and therefore blocking several different mechanisms for cancer
growth, may stop tumour growth.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society